Gene expression and epigenetic changes by furan in rat liver

Toxicology

Volumn 292, Issue 2-3, 2012, Pages 63-70

  Chen, Tao ^a   Williams, Tim D ^a   Mally, Angela ^b   Hamberger, Carolin ^b   Mirbahai, Leda ^a   Hickling, Kevin ^c   Chipman, J Kevin ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c ASTRAZENECA   (United Kingdom)

Author keywords

DNA methylation; Furan; Liver; MiRNA; MRNA; Rat

Indexed keywords

DNA; FURAN; MICRORNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE; CHEMICAL ANALYSIS; CHEMICAL CARCINOGENESIS; COMBINED BISULFITE RESTRICTION ANALYSIS; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENOTOXICITY; LIQUID CHROMATOGRAPHY; LIVER CARCINOGENESIS; MALE; MICROARRAY ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; RAT; RNA METHYLATION; TANDEM MASS SPECTROMETRY; UPREGULATION;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; DNA DAMAGE; DNA METHYLATION; EPIGENESIS, GENETIC; FURANS; GENE EXPRESSION REGULATION, NEOPLASTIC; LIVER; LIVER NEOPLASMS; MALE; MICRORNAS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TANDEM MASS SPECTROMETRY;

MUS; RATTUS; RODENTIA;

EID: 84856080822     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.10.020     Document Type: Article

References (37)

1. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
2. Arora D.S., Ramsdale J., Lodge J.P., Wyatt J.I. p53 but not bcl-2 is expressed by most cholangiocarcinomas: a study of 28 cases. Histopathology 1999, 34:497-501.
3. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
4. Bastide K., Guilly M.N., Bernaudin J.F., Joubert C., Lectard B., Levalois C., Malfoy B., Chevillard S. Molecular analysis of the Ink4a/Rb1-Arf/Tp53 pathways in radon-induced rat lung tumors. Lung Cancer 2009, 63:348-353.
5. Chen L., Yan H.X., Yang W., Hu L., Yu L.X., Liu Q., Li L., Huang D.D., Ding J., Shen F., et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J. Hepatol. 2009, 50:358-369.
6. Chen T., Mally A., Ozden S., Chipman J.K. Low doses of the carcinogen furan alter cell cycle and apoptosis gene expression in rat liver independent of DNA methylation. Environ. Health Perspect. 2010, 118:1597-1602.
7. Dong Y., Walsh M.D., McGuckin M.A., Gabrielli B.G., Cummings M.C., Wright R.G., Hurst T., Khoo S.K., Parsons P.G. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int. J. Cancer 1997, 74:57-63.
8. Durling L.J., Svensson K., Abramsson-Zetterberg L. Furan is not genotoxic in the micronucleus assay in vivo or in vitro. Toxicol. Lett. 2007, 169:43-50.
9. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999, 13:2658-2669.
10. Ferru A., Fromont G., Gibelin H., Guilhot J., Savagner F., Tourani J.M., Kraimps J.L., Larsen C.J., Karayan-Tapon L. The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression. Br. J. Cancer 2006, 95:1670-1677.
11. Food and Drug Administration Exploratory Data on Furan in Food 2004, vol. 2011. http://www.cfsan.fda.gov/~dms/furandat.html.
12. Fransson-Steen R., Goldsworthy T.L., Kedderis G.L., Maronpot R.R. Furan-induced liver cell proliferation and apoptosis in female B6C3F1 mice. Toxicology 1997, 118:195-204.
13. Furubo S., Harada K., Shimonishi T., Katayanagi K., Tsui W., Nakanuma Y. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology 1999, 35:230-240.
14. Henshall S.M., Quinn D.I., Lee C.S., Head D.R., Golovsky D., Brenner P.C., Delprado W., Stricker P.D., Grygiel J.J., Sutherland R.L. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin. Cancer Res. 2001, 7:544-550.
15. Hickling K.C., Hitchcock J.M., Oreffo V., Mally A., Hammond T.G., Evans J.G., Chipman J.K. Evidence of oxidative stress and associated DNA damage, increased proliferative drive, and altered gene expression in rat liver produced by the cholangiocarcinogenic agent furan. Toxicol. Pathol. 2010, 38:230-243.
16. Hui R., Macmillan R.D., Kenny F.S., Musgrove E.A., Blamey R.W., Nicholson R.I., Robertson J.F., Sutherland R.L. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin. Cancer Res. 2000, 6:2777-2787.
17. Humbey O., Pimkina J., Zilfou J.T., Jarnik M., Dominguez-Brauer C., Burgess D.J., Eischen C.M., Murphy M.E. The ARF tumor suppressor can promote the progression of some tumors. Cancer Res. 2008, 68:9608-9613.
18. Hunt A.E., Moule M.G., Fried M. The rat ARF protein is translated from two closely spaced ATG start codons and can transcriptionally activate p53 in the absence of p53 protein stabilization. Cell Cycle 2006, 5:1324-1330.
19. International Agency for Research on Cancer Summaries & Evaluations 1995, vol. 2011. p. 393. http://www.inchem.org/documents/iarc/vol63/furan.html.
20. Irizarry R.A., Ladd-Acosta C., Wen B., Wu Z., Montano C., Onyango P., Cui H., Gabo K., Rongione M., Webster M., et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 2009, 41:178-186.
21. Itoi T., Takei K., Shinohara Y., Takeda K., Nakamura K., Horibe T., Sanada A., Ohno H., Matsubayashi H., Saito T., Watanabe H. K-ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers. Pathol. Int. 1999, 49:30-37.
22. Kang Y.K., Kim W.H., Lee H.W., Lee H.K., Kim Y.I. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab. Invest. 1999, 79:477-483.
23. Kellert M., Brink A., Richter I., Schlatter J., Lutz W.K. Tests for genotoxicity and mutagenicity of furan and its metabolite cis-2-butene-1,4-dial in L5178Y tk+/- mouse lymphoma cells. Mutat. Res. 2008, 657:127-132.
24. Kim K.T., Han S.Y., Jeong J.S. Expression of G1 cell cycle regulators in rat liver upon repeated exposure to thioacetamide. Korean J. Hepatol. 2007, 13:81-90.
25. Ludwig L., Oswald F., Hoang-Vu C., Dralle H., Hildt E., Schmid R.M., Karges W. Expression of the Grb2-related RET adapter protein Grap-2 in human medullary thyroid carcinoma. Cancer Lett. 2009, 275:194-197.
26. Mally A., Graff C., Schmal O., Moro S., Hamberger C., Schauer U.M., Brück J., Ozden S., Sieber M., Steger U., Schrenk D., Hard G.C., Chipman J.K., Dekant W. Functional and proliferative effects of repeated low-dose oral administration of furan in rat liver. Mol. Nutr. Food Res. 2009, 54:1556-1567.
27. Maronpot R.R., Giles H.D., Dykes D.J., Irwin R.D. Furan-induced hepatic cholangiocarcinomas in Fischer 344 rats. Toxicol. Pathol. 1991, 19:561-570.
28. Meng F., Henson R., Lang M., Wehbe H., Maheshwari S., Mendell J.T., Jiang J., Schmittgen T.D., Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-2129.
29. Mugford C.A., Carfagna M.A., Kedderis G.L. Furan-mediated uncoupling of hepatic oxidative phosphorylation in Fischer-344 rats: an early event in cell death. Toxicol. Appl. Pharmacol. 1997, 144:1-11.
30. National Toxicology Program Toxicology and carcinogenesis studies of furan (CAS No 110-00-9) in F344 rats and B6C3F1 mice(gavage studies). Natl. Toxicol. Program Tech. Rep. Ser. 1993, 402:1-286.
31. Ozenne P., Eymin B., Brambilla E., Gazzeri S. The ARF tumor suppressor: structure, functions and status in cancer. Int. J. Cancer 2010, 127:2239-2247.
32. Sandhu D.S., Shire A.M., Roberts L.R. Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets. Liver Int. 2008, 28:12-27.
33. Sharpless N.E. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 2005, 576:22-38.
34. Sirica A.E. Biliary proliferation and adaptation in furan-induced rat liver injury and carcinogenesis. Toxicol. Pathol. 1996, 24:90-99.
35. Tannapfel A., Benicke M., Katalinic A., Uhlmann D., Kockerling F., Hauss J., Wittekind C. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000, 47:721-727.
36. Wilson D.M., Goldsworthy T.L., Popp J.A., Butterworth B.E. Evaluation of genotoxicity, pathological lesions, and cell proliferation in livers of rats and mice treated with furan. Environ. Mol. Mutagen. 1992, 19:209-222.
37. Yang B., House M.G., Guo M., Herman J.G., Clark D.P. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod. Pathol. 2005, 18:412-420.